Superworth

CRISPR Therapeutics market cap CRSP

Share price times shares outstanding: what the whole company sells for, since 2016.

Today, Nov 2, 2026
$4.8B
Highest close in our data
$14.1B
Jan 2021

CRISPR Therapeutics is worth $4.8B at the close on Nov 2, 2026, at $49.99 a share.

That is down 4% over the last year and down 30% over five years.

Its highest close in our data was $14.1B in Jan 2021.

Market cap over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHighChange
2026 so far$4.8B$4.4B$5.8B−8%
2025$5.2B$2.8B$6.6B+54%
2024$3.4B$3.4B$6.7B−31%
2023$5B$3.1B$5.6B+56%
2022$3.2B$3.2B$6.5B−45%
2021$5.8B$5.4B$14.1B−46%
2020$10.8B$2.3B$11.9B+197%
2019$3.6B$1.6B$4B+162%
2018$1.4B$1.1B$3.3B+44%
2017$963.1M$569.6M$963.1M+19%
2016$806.5M$757.6M$830.4Mn/a

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

CompanyMarket cap
CRSPCRISPR Therapeutics$4.8B
KRYSKrystal Biotech$8.8B
ADMAAdma Biologics$2.5B
RGENRepligen$9.8B
VCELVericel$2.1B
TECHBIO-TECHNE$11.4B
HALOHalozyme Therapeutics$14.6B
NBIXNeurocrine Biosciences$14.8B
EXELExelixis$17.4B
ALNYAlnylam Pharmaceuticals$21.2B
INCYIncyte$24.3B
Peer median$13B

What the market cap tells you

Share price times shares outstanding: what the whole company sells for today.

Size, not quality. Large caps move slower and are covered more. That is all it tells you.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.